Earnings Call Excerpt
Millennium Pharmaceuticals, Inc. (MLNM)
Q1 2006 Earnings Conference Call
April 27th 2006, 7:30 AM.
Executives:
Kyle Kuvalanka, Director, Investor and Corporate Communications
Marsha Fanucci, Chief Financial Officer and SVP, Corporate Strategy
Robert Tepper, President, R&D
Deborah Dunsire, President and Chief Executive Officer
Christophe Bianchi, EVP of Commercial Operations
Nancy Simonian, SVP, Clinical, Regulatory and Medical Affairs
Lisa Adler, Vice President of Corporate Communications
Analysts:
Philip Nadeau, Cowen & Company
Christopher Raymond, Robert W. Baird
Craig Parker, Lehman Brothers
Tom McGahren, Merrill Lynch
Tim Smith, Citigroup
MayKin Ho, Goldman Sachs.
Chris Metropolis, JP Morgan
David Witzke, Banc of America Securities
Bret Holley, CIBC World Markets
Sapna Srivastava, Morgan Stanley
Jim Reddoch, FBR
Presentation
Operator
Good day everyone, thank you for holding and welcome to Millennium Pharmaceuticals First Quarter Earnings Conference Call. Operator Instructions At this time, I would like to introduce your host for today's call, Mr. Kyle Kuvalanka, Director, Investor and Corporate Communications at Millennium Pharmaceuticals. Please go ahead, sir.
Kyle Kuvalanka, Director, Investor and Corporate Communications
Hello everyone and thanks for joining us a little early this morning. Today is an exciting day for Millennium as we opened the NASDAQ market and celebrate our first quarter of non-GAAP profitability in 2006 as well as our 10th anniversary on the NASDAQ.
With me today, in New York, at the NASDAQ market site are Dr. Deborah Dunsire, our President and Chief Executive Officer; Marsha Fanucci, Chief Financial Officer and Senior Vice President of Corporate Strategy; Dr. Bob Tepper, President of Research and Development; Dr. Christophe Bianchi, Executive Vice President of Commercial; Dr. Nancy Simonian, Senior Vice President of Clinical, Regulatory and Medical Affairs; and Lisa Adler, Vice President of Corporate Communications.
The agenda of our prepared remarks is as follows. Marsha will open with an overview of our financial results. Bob will provide an overview of our R&D activities for the quarter, and then Deborah will then provide her view of our activities this quarter. We will then wrap up with Q&A.
Before we begin though, let me remind you that we will be making forward-looking statements, when we discuss our growth signs, products and prospects, a point of reference is how we as a company think, expect or believe the future will look based on information as we know it today. No one can predict the future and there are risks that could cause the company's actual results to differ materially from these statements. You can review a list and description of these risks in the reports we filed with the Securities and Exchange Commission.
- To read the full transcript on Seeking Alpha, click here »
